HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.

Abstract
The purpose of this pooled analysis was to synthesize all available data so as to evaluate the efficacy and safety of lenalidomide in patients with POEMS syndrome. Eligible articles were identified by a search in MEDLINE and ClinicalTrials.gov databases using a predefined combination. Eligible cases of patients treated in our department were additionally included. Overall, 51 patients were included. The median age of patients was 54.5 years (range: 32-79 years). Lenalidomide was given as first- or second-line treatment in 28.6% and 47.6% of patients, respectively. Hematological responses included complete response in 18.6%, very good partial response in 39.5% and partial response in 37.2% of cases. Vascular endothelial growth factor (VEGF) reduction was reported in all cases. Neuropathy improved in 92.0% of cases and stabilized in 8%. The progression-free survival (PFS) estimate at 12 months was 93.9%. Lenalidomide can represent a safe and effective option for the treatment of patients with POEMS.
AuthorsFlora Zagouri, Efstathios Kastritis, Maria Gavriatopoulou, Theodoros N Sergentanis, Theodora Psaltopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 55 Issue 9 Pg. 2018-23 (Sep 2014) ISSN: 1029-2403 [Electronic] United States
PMID24295131 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
Chemical References
  • Angiogenesis Inhibitors
  • Immunologic Factors
  • Thalidomide
  • Lenalidomide
Topics
  • Adult
  • Aged
  • Angiogenesis Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Humans
  • Immunologic Factors (administration & dosage, adverse effects, therapeutic use)
  • Lenalidomide
  • Middle Aged
  • POEMS Syndrome (drug therapy, mortality)
  • Thalidomide (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: